Retraction: Myocardial Remodeling in Diabetic Cardiomyopathy Associated with Cardiac Mast Cell Activation (PLoS ONE (2013) 8:3 (e60827) DOI: 10.1371/journal.pone.0060827);Myocardial Remodeling in Diabetic Cardiomyopathy Associated with Cardiac Mast Cell Activation

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Huang, Zhi Gang ^a   Jin, Qun ^b   Fan, Min ^a   Cong, Xiao Liang ^a   Han, Shu Fang ^b   Gao, Hai ^c   Shan, Yi ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b JINAN MILITARY GENERAL HOSPITAL   (China)

^c Haiyang People s Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMASE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; NEDOCROMIL; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR PARAMETERS; CELL ACTIVATION; CELL DENSITY; CELL FUNCTION; CELLULAR SECRETION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC CARDIOMYOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME RELEASE; HEART DISEASE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE REMODELING; MALE; MAST CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TREATMENT DURATION;

EID: 84875484048     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0305584     Document Type: Erratum

References (42)

1. Asghar O, Al-Sunni A, Khavandi K, Khavandi A, Withers S, et al. (2009) Diabetic cardiomyopathy. Clin Sci (Lond) 116: 741-760.
2. Liu JW, Liu D, Cui KZ, Xu Y, Li YB, et al. (2012) Recent advances in understanding the biochemical and molecular mechanism of diabetic cardiomyopathy. Biochem Biophys Res Commun 427: 441-443.
3. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME, (2008) Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 121: 748-757.
4. Miki T, Yuda S, Kouzu H, Miura T (2012) Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev.
5. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, et al. (2002) Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 346: 1699-1705.
6. Mathias CB, Freyschmidt EJ, Caplan B, Jones T, Poddighe D, et al. (2009) IgE influences the number and function of mature mast cells, but not progenitor recruitment in allergic pulmonary inflammation. J Immunol 182: 2416-2424.
7. Rottem M, Mekori YA, (2005) Mast cells and autoimmunity. Autoimmun Rev 4: 21-27.
8. Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, et al. (2012) Mast cells and inflammation. Biochim Biophys Acta 1822: 21-33.
9. Abraham SN, St John AL, (2010) Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10: 440-452.
10. Patella V, de Crescenzo G, Ciccarelli A, Marino I, Adt M, et al. (1995) Human heart mast cells: a definitive case of mast cell heterogeneity. Int Arch Allergy Immunol 106: 386-393.
11. Theoharides TC, Sismanopoulos N, Delivanis DA, Zhang B, Hatziagelaki EE, et al. (2011) Mast cells squeeze the heart and stretch the gird: their role in atherosclerosis and obesity. Trends Pharmacol Sci 32: 534-542.
12. Caughey GH, (2007) Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev 217: 141-154.
13. Metcalfe DD, Baram D, Mekori YA, (1997) Mast cells. Physiol Rev 77: 1033-1079.
14. Dvorak AM, (1986) Mast-cell degranulation in human hearts. N Engl J Med 315: 969-970.
15. Patella V, de Crescenzo G, Lamparter-Schummert B, De Rosa G, Adt M, et al. (1997) Increased cardiac mast cell density and mediator release in patients with dilated cardiomyopathy. Inflamm Res 46Suppl 1: S31-32.
16. Levick SP, McLarty JL, Murray DB, Freeman RM, Carver WE, et al. (2009) Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension 53: 1041-1047.
17. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, et al. (2003) Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 107: 2555-2558.
18. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A, (1990) Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 66: 883-890.
19. Balcells E, Meng QC, Johnson WH Jr, Oparil S, Dell'Italia LJ, (1997) Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 273: H1769-1774.
20. Brower GL, Chancey AL, Thanigaraj S, Matsubara BB, Janicki JS, (2002) Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol 283: H518-525.
21. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, et al. (2005) A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 280: 9291-9296.
22. Marshall JS, Leal-Berumen I, Nielsen L, Glibetic M, Jordana M, (1996) Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J Clin Invest 97: 1122-1128.
23. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, et al. (2003) IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 4: 551-556.
24. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A, (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147: 3815-3822.
25. Levick SP, Gardner JD, Holland M, Hauer-Jensen M, Janicki JS, et al. (2008) Protection from adverse myocardial remodeling secondary to chronic volume overload in mast cell deficient rats. J Mol Cell Cardiol 45: 56-61.
26. Rajesh M, Mukhopadhyay P, Batkai S, Patel V, Saito K, et al. (2010) Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 56: 2115-2125.
27. Doring HJ, (1990) The isolated perfused heart according to Langendorff technique--function--application. Physiol Bohemoslov 39: 481-504.
28. Mukhopadhyay P, Batkai S, Rajesh M, Czifra N, Harvey-White J, et al. (2007) Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 50: 528-536.
29. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA, (2008) Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 3: 1422-1434.
30. Li J, Zhu H, Shen E, Wan L, Arnold JM, et al. (2010) Deficiency of rac1 blocks NADPH oxidase activation, inhibits endoplasmic reticulum stress, and reduces myocardial remodeling in a mouse model of type 1 diabetes. Diabetes 59: 2033-2042.
31. Li Y, Ma J, Zhu H, Singh M, Hill D, et al. (2011) Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. Diabetes 60: 2985-2994.
32. Krishnamurthy P, Rajasingh J, Lambers E, Qin G, Losordo DW, et al. (2009) IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res 104: e9-18.
33. Panizo A, Mindan FJ, Galindo MF, Cenarruzabeitia E, Hernandez M, et al. (1995) Are mast cells involved in hypertensive heart disease? J Hypertens 13: 1201-1208.
34. Zhao XY, Zhao LY, Zheng QS, Su JL, Guan H, et al. (2008) Chymase induces profibrotic response via transforming growth factor-beta 1/Smad activation in rat cardiac fibroblasts. Mol Cell Biochem 310: 159-166.
35. Oyamada S, Bianchi C, Takai S, Chu LM, Sellke FW, (2011) Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J Pharmacol Exp Ther 339: 143-151.
36. Murray DB, Levick SP, Brower GL, Janicki JS, (2010) Inhibition of matrix metalloproteinase activity prevents increases in myocardial tumor necrosis factor-alpha. J Mol Cell Cardiol 49: 245-250.
37. Gurantz D, Cowling RT, Varki N, Frikovsky E, Moore CD, et al. (2005) IL-1beta and TNF-alpha upregulate angiotensin II type 1 (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart. J Mol Cell Cardiol 38: 505-515.
38. Sun M, Chen M, Dawood F, Zurawska U, Li JY, et al. (2007) Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 115: 1398-1407.
39. Nelson N, Kanno Y, Hong C, Contursi C, Fujita T, et al. (1996) Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation. J Immunol 156: 3711-3720.
40. Yu Q, Horak K, Larson DF, (2006) Role of T lymphocytes in hypertension-induced cardiac extracellular matrix remodeling. Hypertension 48: 98-104.
41. Shiota N, Rysa J, Kovanen PT, Ruskoaho H, Kokkonen JO, et al. (2003) A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens 21: 1935-1944.
42. Andrzejczak D, Gorska D, Czarnecka E, (2006) Influence of amlodipine and atenolol on lipopolysaccharide (LPS)-induced serum concentrations of TNF-alpha, IL-1, IL-6 in spontaneously hypertensive rats (SHR). Pharmacol Rep 58: 711-719.